AAPL 169.89 0.5147% MSFT 399.04 -2.4495% GOOG 157.95 -1.9553% GOOGL 156.0 -1.9669% AMZN 173.67 -1.6535% NVDA 826.32 3.7087% META 441.38 -10.5613% TSLA 170.18 4.9652% TSM 136.58 2.7149% LLY 724.87 -1.0011% V 275.16 0.0509% AVGO 1294.42 2.9917% JPM 193.37 0.1502% UNH 493.86 1.3462% NVO 125.79 -0.2933% WMT 60.21 0.5679% LVMUY 167.91 -2.1618% XOM 121.35 0.2478% LVMHF 837.0 -2.6461% MA 462.11 -0.0843%
Last update at 2024-04-25T20:14:00Z
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 16444.00M | 13879.00M | 8791.00M | 11464.00M | 8701.00M |
| Minority interest | -7.00000M | 691.00M | 15.00M | -66.00000M | -27.00000M |
| Net income | 14519.00M | 13049.00M | 7067.00M | 9843.00M | 6220.00M |
| Selling general administrative | 9772.00M | 9293.00M | 10468.00M | 10615.00M | 10102.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 41872.00M | 35078.00M | 32509.00M | 32728.00M | 28785.00M |
| Reconciled depreciation | 3909.00M | 3214.00M | 3625.00M | 3652.00M | 4519.00M |
| Ebit | 14710.00M | 10646.00M | 5436.00M | 9227.00M | 5731.00M |
| Ebitda | 18619.00M | 13860.00M | 9061.00M | 12879.00M | 10250.00M |
| Depreciation and amortization | 3909.00M | 3214.00M | 3625.00M | 3652.00M | 4519.00M |
| Non operating income net other | -1501.00000M | 1341.00M | 886.00M | -139.00000M | 402.00M |
| Operating income | 14710.00M | 10646.00M | 5436.00M | 9227.00M | 8931.00M |
| Other operating expenses | 41001.00M | 35505.00M | 39511.00M | 34599.00M | 33363.00M |
| Interest expense | 962.00M | 806.00M | 831.00M | 893.00M | 772.00M |
| Tax provision | 1918.00M | 1521.00M | 1709.00M | 1687.00M | 2508.00M |
| Interest income | 1348.00M | 1884.00M | 59.00M | 274.00M | 343.00M |
| Net interest income | -805.00000M | -770.00000M | -772.00000M | -619.00000M | -429.00000M |
| Extraordinary items | 0.00000M | 704.00M | 2548.00M | -117.00000M | -289.00000M |
| Non recurring | 337.00M | 661.00M | 578.00M | 638.00M | 632.00M |
| Other items | - | - | - | - | - |
| Income tax expense | 1918.00M | 1521.00M | 1709.00M | 1687.00M | 2508.00M |
| Total revenue | 59283.00M | 48704.00M | 47994.00M | 46840.00M | 42294.00M |
| Total operating expenses | 23590.00M | 21879.00M | 24026.00M | 20487.00M | 19854.00M |
| Cost of revenue | 17411.00M | 13626.00M | 15485.00M | 14112.00M | 13509.00M |
| Total other income expense net | 1734.00M | 3233.00M | 3355.00M | 2237.00M | 199.00M |
| Discontinued operations | - | 704.00M | 704.00M | 704.00M | 704.00M |
| Net income from continuing ops | 14526.00M | 12358.00M | 7082.00M | 9777.00M | 6193.00M |
| Net income applicable to common shares | 14519.00M | 13049.00M | 7067.00M | 9843.00M | 6220.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 109160.00M | 105694.00M | 91588.00M | 84397.00M | 82637.00M |
| Intangible assets | 20269.00M | 22933.00M | 14604.00M | 14196.00M | 11431.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 7169.00M | 6987.00M | 5541.00M | 4277.00M | 4500.00M |
| Total liab | 63102.00M | 67437.00M | 66184.00M | 58396.00M | 55755.00M |
| Total stockholder equity | 45991.00M | 38184.00M | 25317.00M | 25907.00M | 26701.00M |
| Deferred long term liab | 1795.00M | 3441.00M | 1015.00M | 1470.00M | 1702.00M |
| Other current liab | 18029.00M | 16851.00M | 16302.00M | 14872.00M | 13580.00M |
| Common stock | 1788.00M | 1788.00M | 1788.00M | 1788.00M | 1788.00M |
| Capital stock | 1788.00M | 1788.00M | 1788.00M | 1788.00M | 1788.00M |
| Retained earnings | 61081.00M | 53696.00M | 47362.00M | 46602.00M | 42579.00M |
| Other liab | 9105.00M | 11650.00M | 12135.00M | 12672.00M | 13662.00M |
| Good will | 21204.00M | 21264.00M | 20238.00M | 19425.00M | 18253.00M |
| Other assets | 7350.00M | 9400.00M | 7846.00M | 5263.00M | 5313.00M |
| Cash | 12694.00M | 8096.00M | 8062.00M | 9676.00M | 7965.00M |
| Cash and equivalents | 12694.00M | 8096.00M | 8062.00M | 9676.00M | 7965.00M |
| Total current liabilities | 24239.00M | 23872.00M | 27327.00M | 22220.00M | 22206.00M |
| Current deferred revenue | - | - | 1015.00M | - | - |
| Net debt | 17997.00M | 25006.00M | 23729.00M | 16670.00M | 17149.00M |
| Short term debt | 1946.00M | 2412.00M | 6431.00M | 3610.00M | 5308.00M |
| Short long term debt | 1946.00M | 2412.00M | 6431.00M | 3610.00M | 5308.00M |
| Short long term debt total | 30691.00M | 33102.00M | 31791.00M | 26346.00M | 25114.00M |
| Other stockholder equity | -12110.00000M | -12871.00000M | -17199.00000M | -16290.00000M | -12121.00000M |
| Property plant equipment | 21422.00M | 19279.00M | 17986.00M | 15053.00M | 13291.00M |
| Total current assets | 35722.00M | 30266.00M | 27764.00M | 27483.00M | 25875.00M |
| Long term investments | 1015.00M | 370.00M | 785.00M | 1469.00M | 6233.00M |
| Net tangible assets | 4518.00M | 3548.00M | -9525.00000M | -7714.00000M | -2983.00000M |
| Short term investments | 498.00M | - | 785.00M | 774.00M | 899.00M |
| Net receivables | 9450.00M | 9230.00M | 7851.00M | 6778.00M | 7071.00M |
| Long term debt | 28745.00M | 30690.00M | 25360.00M | 22736.00M | 19806.00M |
| Inventory | 5911.00M | 5953.00M | 6310.00M | 5978.00M | 5440.00M |
| Accounts payable | 4264.00M | 4609.00M | 4594.00M | 3738.00M | 3318.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | 67.00M | 73.00M | 87.00M | 94.00M | 181.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -4768.00000M | -4429.00000M | -6634.00000M | -6193.00000M | -5545.00000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | 1788.00M | 1788.00M | 1788.00M | 1788.00M | 1788.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | 61081.00M | 53696.00M | 47362.00M | 46602.00M | 42579.00M |
| Treasury stock | - | -57109.00000M | -56787.00000M | -55950.00000M | -50929.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 7733.00M | 8141.00M | 9196.00M | 5301.00M | 5852.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 73438.00M | 75428.00M | 63824.00M | 56914.00M | 56762.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | 28745.00M | 30690.00M | 25360.00M | 22736.00M | 19806.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -483.00000M | 1025.00M | 1717.00M | 5420.00M | 7258.00M |
| Change to liabilities | -504.00000M | 626.00M | -307.00000M | -1821.00000M | 450.00M |
| Total cashflows from investing activities | -4960.00000M | -16421.00000M | -9443.00000M | -2629.00000M | 4314.00M |
| Net borrowings | -2251.00000M | 1631.00M | 5011.00M | 1248.00M | 837.00M |
| Total cash from financing activities | -9119.00000M | 2593.00M | -2832.00000M | -8861.00000M | -13160.00000M |
| Change to operating activities | -2068.00000M | -997.00000M | -4017.00000M | 107.00M | -1281.00000M |
| Net income | 14526.00M | 12358.00M | 7082.00M | 9777.00M | 6193.00M |
| Change in cash | 4606.00M | 14.00M | -1769.00000M | 1967.00M | 1871.00M |
| Begin period cash flow | 8167.00M | 8153.00M | 9934.00M | 7967.00M | 6096.00M |
| End period cash flow | 12773.00M | 8167.00M | 8165.00M | 9934.00M | 7967.00M |
| Total cash from operating activities | 19095.00M | 14109.00M | 10253.00M | 13440.00M | 10922.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 3909.00M | 3214.00M | 3625.00M | 3652.00M | 4519.00M |
| Other cashflows from investing activities | -89.00000M | -13132.00000M | -6476.00000M | -4576.00000M | -329.00000M |
| Dividends paid | -7012.00000M | -6610.00000M | -6215.00000M | -5695.00000M | 5172.00M |
| Change to inventory | -161.00000M | -674.00000M | -855.00000M | -508.00000M | -911.00000M |
| Change to account receivables | -644.00000M | -2033.00000M | -1002.00000M | 294.00M | -418.00000M |
| Sale purchase of stock | 384.00M | -840.00000M | -1281.00000M | -4780.00000M | -9091.00000M |
| Other cashflows from financing activities | 144.00M | 8714.00M | -436.00000M | 1614.00M | -325.00000M |
| Change to netincome | 2023.00M | 2760.00M | 1476.00M | 2078.00M | 1113.00M |
| Capital expenditures | 4388.00M | 4448.00M | 4684.00M | 3473.00M | 2615.00M |
| Change receivables | -644.00000M | -2033.00000M | -1002.00000M | 294.00M | -418.00000M |
| Cash flows other operating | 14472.00M | 10216.00M | 234.00M | -32.00000M | -24.00000M |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | 5016.00M | -202.00000M | -2022.00000M | 1950.00M | 2076.00M |
| Change in working capital | -2782.00000M | -3839.00000M | -4590.00000M | -2067.00000M | -1553.00000M |
| Stock based compensation | 541.00M | 479.00M | 475.00M | 417.00M | 348.00M |
| Other non cash items | 4469.00M | 1710.00M | 4329.00M | 2217.00M | 1924.00M |
| Free cash flow | 14707.00M | 9661.00M | 5569.00M | 9967.00M | 8307.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| MRK Merck & Company Inc |
3.70 2.91% | 130.70 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
| LLY Eli Lilly and Company |
-7.33 1.00% | 724.87 | 103.14 | 46.73 | 16.88 | 48.24 | 17.43 | 69.11 |
| JNJ Johnson & Johnson |
-1.71 1.15% | 146.82 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
-0.51 0.30% | 167.29 | 42.38 | 13.68 | 4.88 | 22.14 | 5.72 | 31.93 |
| RHHVF Roche Holding AG Participation |
-3.794 1.57% | 237.72 | 17.21 | 12.08 | 3.61 | 7.37 | 4.15 | 13.04 |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV, as well as a collaboration with Bionomics to identify novel a7 nAChR PAMs suitable for the treatment of cognitive disorder; and clinical trial collaboration and supply agreement with Ankyra Therapeutics to evaluate ANK-101 in combination with KEYTRUDA (pembrolizumab) in patients with advanced solid tumors, as well as a clinical trial collaboration and supply agreement with Phanes Therapeutics, Inc. to evaluate PT886 in combination with KEYTRUDA for the treatment of claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas, as well as a development and commercialization agreement with Daiichi Sankyo Company, Limited to jointly develop and commercialize Daiichi Sankyo's DXd antibody drug conjugate (ADC) candidates and a collaboration with HiberCell, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert M. Davis J.D. | CEO & Chairman | 1967 |
| Ms. Caroline Litchfield | Exec. VP & CFO | 1969 |
| Mr. Richard R. DeLuca Jr. | Exec. VP & Pres of Merck Animal Health | 1963 |
| Dr. Dean Y. Li M.D., Ph.D. | Exec. VP & Pres of Merck Research Laboratories | 1962 |
| Mr. David Michael Williams | Exec. VP and Chief Information & Digital Officer | 1969 |
| Mr. Peter Dannenbaum | VP of Investor Relations | NA |
| Ms. Jennifer L. Zachary | Exec. VP & Gen. Counsel | 1978 |
| Lisa LeCointe-Cephas | Sr. VP and Chief Ethics & Compliance Officer | 1982 |
| Ms. Jennifer Mauer | VP of Global Communications | NA |
| Ms. Cristal N. Downing | Exec. VP and Chief Communications & Public Affairs Officer | 1969 |
Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
US 
AU
UK
CA
NZ
Please wait processing your request...